Poland· PL-100308640

Atosiban SUN

A atosiban product containing atosibanum, registered in Poland by Sun Pharmaceutical Industries Europe B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC G02CX01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAtosiban SUNATCG02CX01REGISTER NO.PL-100308640PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Atosiban is registered in 14 of 19 countries.

Countries holding a registration under ATC G02CX01 (atosiban), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose

Atosiban · ATC G02CX01

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Atosibanum
Manufacturer
Sun Pharmaceutical Industries Europe B.V.
Country
Poland (PL)
ATC code
G02CX01
ATC class
Atosiban
Defined daily dose
165 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991283445

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Atosiban in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All atosiban products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Austria · Atosiban Altan, Atosiban Ever Pharma
  • Belgium · Atosiban Ever Pharma
  • Bulgaria · Атозибан Ever Pharma
  • Czechia · Atosiban Avmc, Atosiban Ever Pharma
  • Germany · Atosiban Ever Pharma, Atosiban Ibisqus
  • Denmark · Atosiban Ever Pharma
  • Spain · Atosiban Altan Pharmaceuticals, S.A., Atosiban Ever Pharma
  • Finland · Atosiban Ever Pharma
  • France · Atosiban Altan, Atosiban Altan Pharmaceuticals, S.A.
  • United Kingdom (Northern Ireland) · Atosiban Ibigen
  • Greece · Atosiban Ever Pharma
  • Croatia · Atosiban Ever Pharma, Atosiban Makpharm
  • Iceland · Atosiban Sun, Tractocile
  • Italy · Atosiban Ever Pharma, Atosiban Ibisqus
  • Liechtenstein · Tractocile
  • Luxembourg · Atosiban Ever Pharma
  • Latvia · Atosiban Pharmidea
  • Netherlands · Atosiban Accord, Atosiban Ever Pharma
  • Norway · Atosiban Ever Pharma, Atosiban Sun
  • Portugal · Atosiban Ever Pharma, Atosibano Altan
  • Sweden · Atosiban Accord, Atosiban Ever Pharma
  • Slovenia · Atoziban Ever Pharma
  • Slovakia · Atosiban Ardez

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/03ac430d-ee78-4396-8cd7-b5f4b32969d8
GET /v1/drugs/03ac430d-ee78-4396-8cd7-b5f4b32969d8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Koncentrat do sporządzania roztworu do infuzji",
  "source": "urpl",
  "strength": "37,5 mg/5 ml",
  "packaging": "05909991283445 ¦ Rpz ¦ EU/1/13/852/002 ¦ 29577\n1 fiol. 5 ml",
  "substance": "Atosibanum 37,5 mg/5 ml",
  "common_name": "Atosibanum",
  "pl_product_id": "100308640",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about atosiban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.